Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer (British Journal of Cancer, (2023), 128, 1, (30-41), 10.1038/s41416-022-02025-9)

Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer (British Journal of Cancer, (2023), 128, 1, (30-41), 10.1038/s41416-022-02025-9)'. Together they form a unique fingerprint.

Arts and Humanities

Psychology

Material Science

Social Sciences